Patents Assigned to Bavarian Nordic A/S
  • Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
    Patent number: 9717787
    Abstract: Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant MVA vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein. Also provided herein are products, methods and uses thereof, e.g., suitable to affect an immune response in a subject, or suitable to diagnose an RSV infection, as well as to determine whether a subject is at risk of recurrent RSV infection.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: August 1, 2017
    Assignee: BAVARIAN NORDIC A/S
    Inventors: Cédric Cheminay, Robin Steigerwald, Paul Chaplin
  • Vector Comprising Multiple Homologous Nucleotide Sequences
    Publication number: 20170211098
    Abstract: The invention relates to vectors comprising two or more homologous nucleotide sequences and methods for generating them. The invention concerns substituting bases in the homologous nucleotide sequences with different bases that do not alter the encoded amino acid sequence. The invention allows for the reduction of intramolecular recombination between homologous nucleotide sequences, in particular in mammalian cells. The invention further relates to nucleotide sequences containing substituted bases.
    Type: Application
    Filed: January 5, 2017
    Publication date: July 27, 2017
    Applicant: BAVARIAN NORDIC A/S
    Inventor: Robin STEIGERWALD
  • Single high dose of MVA induces a protective immune response in neonates and infants
    Patent number: 9707291
    Abstract: The invention relates to compositions and methods for inducing a protective immune response against a poxvirus in a human neonate or infant of less than 6 months of age. The invention encompasses administering a single high dose of an MVA to a human neonate or infant of less than 6 months of age, wherein the administration induces protective T- and B-cell responses against a poxvirus in the human neonate or infant.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 18, 2017
    Assignee: BAVARIAN NORDIC A/S
    Inventors: Cédric Cheminay, Ariane Volkmann, Paul Chaplin, Mark Suter
  • AGONISTS AND ANTAGONISTS OF TOLL-LIKE RECEPTOR (TLR) 13
    Publication number: 20170137820
    Abstract: The present invention relates to the field of immunology. The present invention provides agonists and antagonists of Toll-like receptor (TLR) 13. In particular, the present invention provides TLR13 activating and inhibiting nucleic acids, and provides such nucleic acids for use as pharmaceutical agents. The present invention further provides in vitro methods using such nucleic acids.
    Type: Application
    Filed: January 27, 2017
    Publication date: May 18, 2017
    Applicant: Bavarian Nordic A/S
    Inventors: Carsten Kirschning, Stefan Bauer, Hubertus Hochrein
  • USE OF OIL AND WATER EMULSIONS FOR INCREASING B CELL RESPONSES WITH MODIFIED VACCINIA ANKARA VIRUS
    Publication number: 20170128561
    Abstract: The invention relates to compositions, uses, and methods for inducing an immune response against a vaccinia virus. The addition of an oil and water emulsion to MVA can vastly increase the B cell response and particularly neutralizing antibodies against vaccinia virus and encoded recombinant antigens. Thus, the addition of an oil and water emulsion to MVA can increase the protective immune response. The invention encompasses administering a dose of an MVA in an oil and water emulsion to an animal, especially a human.
    Type: Application
    Filed: March 12, 2015
    Publication date: May 11, 2017
    Applicant: Bavarian Nordic A/S
    Inventors: Cédric Cheminay, Robin Steigerwald, Ariane Volkmann
  • Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
    Publication number: 20170106065
    Abstract: The invention relates to compositions, kits, and methods for cancer therapy using recombinant poxviruses encoding a tumor-associated antigen in combination with a monoclonal antibody against immune checkpoint molecule TIM-3.
    Type: Application
    Filed: May 8, 2015
    Publication date: April 20, 2017
    Applicant: Bavarian Nordic A/S
    Inventors: SUSAN FOY, STEFANIE MANDL, RYAN ROUNTREE
  • RECOMBINANT POXVIRUS VECTOR COMPRISING TETANUS TOXIN FRAGMENT C
    Publication number: 20170081642
    Abstract: The present invention relates to a recombinant poxvirus comprising tetanus toxin fragment C for improved immunogenicity of an antigen and related methods and uses. Specifically, the present invention generally relates to genetically engineered (recombinant) poxvirus vectors comprising a tetanus toxin fragment C (TTC) coding sequence operably linked to a bacterial antigenic determinant as well as to uses thereof, e.g., to affect an immune response in a subject.
    Type: Application
    Filed: October 7, 2016
    Publication date: March 23, 2017
    Applicant: Bavarian Nordic A/S
    Inventors: Paul Chaplin, Robin Steigerwald
  • RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE
    Publication number: 20170043008
    Abstract: Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant MVA vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein. Also provided herein are products, methods and uses thereof, e.g., suitable to affect an immune response in a subject, or suitable to diagnose an RSV infection, as well as to determine whether a subject is at risk of recurrent RSV infection.
    Type: Application
    Filed: October 14, 2016
    Publication date: February 16, 2017
    Applicant: Bavarian Nordic A/S
    Inventors: Cédric Cheminay, Robin Steigerwald, Paul Chaplin
  • Agonists and antagonists of toll-like receptor (TLR) 13
    Patent number: 9556439
    Abstract: The present invention relates to the field of immunology. The present invention provides agonists and antagonists of Toll-like receptor (TLR) 13. In particular, the present invention provides TLR13 activating and inhibiting nucleic acids, and provides such nucleic acids for use as pharmaceutical agents. The present invention further provides in vitro methods using such nucleic acids.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: January 31, 2017
    Assignee: BAVARIAN NORDIC A/S
    Inventors: Carsten Kirschning, Stefan Bauer, Hubertus Hochrein
  • Vector comprising multiple homologous nucleotide sequences
    Patent number: 9540660
    Abstract: The invention relates to vectors comprising two or more homologous nucleotide sequences and methods for generating them. The invention concerns substituting bases in the homologous nucleotide sequences with different bases that do not alter the encoded amino acid sequence. The invention allows for the reduction of intramolecular recombination between homologous nucleotide sequences, in particular in mammalian cells. The invention further relates to nucleotide sequences containing substituted bases.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: January 10, 2017
    Assignee: BAVARIAN NORDIC A/S
    Inventor: Robin Steigerwald
  • COMPOSITIONS AND METHODS FOR INDUCING AN ENHANCED IMMUNE RESPONSE USING POXVIRUS VECTORS
    Publication number: 20160376596
    Abstract: Provided herein are recombinant poxviruses comprising heterologous or native nucleic acids specifying excess double-stranded RNA (dsRNA) early in infection, which may further comprise heterologous nucleic acids encoding one or more costimulatory molecules, and/or heterologous nucleic acids encoding one or more infectious disease-associated antigens or tumor-associated antigens, as well as pharmaceutical compositions comprising such recombinant poxviruses and methods and uses thereof. The recombinant poxviruses provided herein enhance innate and adaptive immune activation in subjects compared to identical recombinant poxviruses lacking heterologous or native transcription units specifying excess early dsRNA.
    Type: Application
    Filed: November 25, 2014
    Publication date: December 29, 2016
    Applicant: Bavarian Nordic A/S
    Inventors: Jürgen Hausmann, Michael Wolferstätter
  • Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
    Patent number: 9480738
    Abstract: Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant MVA vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein. Also provided herein are products, methods and uses thereof, e.g., suitable to affect an immune response in a subject, or suitable to diagnose an RSV infection, as well as to determine whether a subject is at risk of recurrent RSV infection.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 1, 2016
    Assignee: BAVARIAN NORDIC A/S
    Inventors: Cédric Cheminay, Robin Steigerwald, Paul Chaplin
  • Recombinant poxvirus vector comprising tetanus toxin fragment C
    Patent number: 9463238
    Abstract: The present invention relates to a recombinant poxvirus comprising tetanus toxin fragment C for improved immunogenicity of an antigen and related methods and uses. Specifically, the present invention generally relates to genetically engineered (recombinant) poxvirus vectors comprising a tetanus toxin fragment C (TTC) coding sequence operably linked to a bacterial antigenic determinant as well as to uses thereof, e.g., to affect an immune response in a subject.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: October 11, 2016
    Assignee: BAVARIAN NORDIC A/S
    Inventors: Paul Chaplin, Robin Steigerwald
  • Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor
    Publication number: 20160271239
    Abstract: The present disclosure encompasses therapies, compositions, and methods for treatment of a human cancer patient using a recombinant poxvirus encoding a tumor-associated antigen in combination with one or more agonists or antagonists of immune checkpoint inhibitors.
    Type: Application
    Filed: October 31, 2014
    Publication date: September 22, 2016
    Applicant: Bavarian Nordic A/S
    Inventors: SUSAN FOY, STEFANIE MANDL, RYAN ROUNTREE, ALAIN DELCAYRE
  • Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents
    Patent number: 9265823
    Abstract: The present invention relates to the rapid induction of a protective immune response against infectious agents using a poxvirus. An immune response can be induced by administering the poxvirus 7 to 2 days prior to infection with the infections agents.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: February 23, 2016
    Assignee: BAVARIAN NORDIC A/S
    Inventors: Paul Chaplin, Luis Mateo
  • SINGLE HIGH DOSE OF MVA INDUCES A PROTECTIVE IMMUNE RESPONSE IN NEONATES AND INFANTS
    Publication number: 20160030551
    Abstract: The invention relates to compositions and methods for inducing a protective immune response against a poxvirus in a human neonate or infant of less than 6 months of age. The invention encompasses administering a single high dose of an MVA to a human neonate or infant of less than 6 months of age, wherein the administration induces protective T- and B-cell responses against a poxvirus in the human neonate or infant.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Applicant: Bavarian Nordic A/S
    Inventors: Cédric Cheminay, Ariane Volkmann, Paul Chaplin, Mark Suter
  • VECTOR COMPRISING MULTIPLE HOMOLOGOUS NUCLEOTIDE SEQUENCES
    Publication number: 20160017369
    Abstract: The invention relates to vectors comprising two or more homologous nucleotide sequences and methods for generating them. The invention concerns substituting bases in the homologous nucleotide sequences with different bases that do not alter the encoded amino acid sequence. The invention allows for the reduction of intramolecular recombination between homologous nucleotide sequences, in particular in mammalian cells. The invention further relates to nucleotide sequences containing substituted bases.
    Type: Application
    Filed: March 9, 2015
    Publication date: January 21, 2016
    Applicant: BAVARIAN NORDIC A/S
    Inventor: Robin STEIGERWALD
  • Recombinant modified vaccinia virus Ankara influenza vaccine
    Patent number: 9173933
    Abstract: The invention concerns a recombinant modified vaccinia virus Ankara (MVA virus) expressing at least two external influenza virus antigens and/or an epitope of one or more of the at least two antigens and at least two internal influenza virus antigens and/or an epitope of the at least two antigens. The invention, thus, concerns a recombinant MVA virus encoding multiple external and/or internal influenza virus antigens, preferably from multiple influenza virus strains. The invention further concerns the use of said recombinant MVA in preparing a medicament and vaccine for influenza virus. Further encompassed by the present invention are methods, composition and kits.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: November 3, 2015
    Assignee: BAVARIAN NORDIC A/S
    Inventors: Josef Weigl, Jürgen Hausmann, Robin Steigerwald
  • PR13.5 PROMOTER FOR ROBUST T-CELL AND ANTIBODY RESPONSES
    Publication number: 20150299267
    Abstract: The invention encompasses recombinant poxviruses, preferably modified Vaccinia Ankara (MVA) viruses, comprising a Pr13.5 promoter operably linked to a nucleotide sequence encoding an antigen and uses thereof. The invention is drawn to compositions and methods for the induction of strong CD8 T cell and antibody responses to a specific antigen(s) by administering one or more immunizations of the recombinant MVA to a mammal, preferably a human.
    Type: Application
    Filed: October 28, 2013
    Publication date: October 22, 2015
    Applicant: BAVARIAN NORDIC A/S
    Inventors: Robin Steigerwald, Kay Brinkmann
  • Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
    Patent number: 9163237
    Abstract: The present invention relates to a replication deficient recombinant virus encoding at least one antigen and/or antigenic epitope, wherein expression of said antigen and/or antigenic epitope is regulated by a transcriptional control element comprising at least two elements driving early expression of said antigen and/or antigenic epitope and the use of said replication deficient recombinant virus as medicament or vaccine.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: October 20, 2015
    Assignee: BAVARIAN NORDIC A/S
    Inventors: Jürgen Hausmann, Karen Baur, Kay Brinkmann